StockData
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc. (COYA) stock

COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3017% above fair value
$3.02+0.02 (+0.67%)

Close on Nov 17, 2026Market cap $70.84MP/E –Yield –

Coya Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Coya Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $22.64M, up 64.9% year over year. For fiscal 2025 it was $16.73M, up 41.0% from the year before. The highest annual figure on record is $16.73M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.73M+41.0%
FY2024Dec 31, 2024$11.87M+115.7%
FY2023Dec 31, 2023$5.50M+24.7%
FY2022Dec 31, 2022$4.41M+73.6%
FY2021Dec 31, 2021$2.54M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$8.57M+193.8%
Q2 FY2026Jun 30, 2026$5.03M+37.3%
Q1 FY2026Mar 31, 2026$4.10M-21.4%
Q4 FY2025Dec 31, 2025$4.94M+155.0%
Q3 FY2025Sep 30, 2025$2.92M+31.2%
Q2 FY2025Jun 30, 2025$3.66M-19.8%
Q1 FY2025Mar 31, 2025$5.21M+66.2%
Q4 FY2024Dec 31, 2024$1.94M+20.4%
Q3 FY2024Sep 30, 2024$2.22M+39.7%
Q2 FY2024Jun 30, 2024$4.57M+327.6%
Q1 FY2024Mar 31, 2024$3.14M+154.8%
Q4 FY2023Dec 31, 2023$1.61M+127.3%
Q3 FY2023Sep 30, 2023$1.59M+24.6%
Q2 FY2023Jun 30, 2023$1.07M-26.2%
Q1 FY2023Mar 31, 2023$1.23M+25.8%
Q4 FY2022Dec 31, 2022$708.03K–
Q3 FY2022Sep 30, 2022$1.28M–
Q2 FY2022Jun 30, 2022$1.45M–
Q1 FY2022Mar 31, 2022$978.80K–

More Coya Therapeutics figures

See a number that looks wrong?